ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO822

Expression of Beta-3 Adrenergic Receptor (β3-AR) in Normal and Pathological Renal Tissue

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Schena, Giorgia, Yale University, New Haven, Connecticut, United States
  • Chiurlia, Samantha, Schena Foundation, Valenzano-Bari, Italy, Italy
  • Cox, Sharon N., University of Bari, Bari, Italy
  • Rossini, M., University of Bari, Department of Emergency and Organ Transplantation, Nephrology Unit, Bari, Italy
  • Capodiferro, Saverio, university of bari, Bari, None Selected, Italy
  • Mastropasqua, Mauro Giuseppe, Policlinico di Bari, Bari, None Selected, Italy
  • Maiorano, Eugenio, Università degli Studi di Bari, Bari, Italy
  • Caplan, Michael J., Yale University School of Medicine, New Haven, Connecticut, United States
  • Schena, Francesco Paolo, University of Bari, Bari, Italy

The β3-adrenoreceptor (β3-AR) is a G-protein coupled receptor whose expression has been reported in multiple nephron segments of the murine kidney, including thin ascending limb (tAL), thick ascending limb (TAL), distal convoluted tubule (DCT) and cortical collecting duct (CCD). However, no information is available regarding β3-AR presence in human kidney. The aim of our study was to investigate the presence of β3-AR at the glomerular and tubular level in normal and pathological human renal tissue.


β3-AR has been detected by immunohistochemistry in 10% formalin- fixed and paraffin-embedded kidney tissue sections of 6 glomerular diseases (GD), 6 autosomal dominant polycystic kidney disease (ADPKD) and 6 normal kidney donors (KD). We used three different β3-AR antibodies: rabbit polyclonal antibody (Biomatik), mouse polyclonal antibody (Abnova) and mouse monoclonal antibody (R&D System). Fluorescence co-localization analysis in combination with specific tubular markers was performed to characterize β3-AR expression in different tubular segments: LPR2 for staining in proximal tubule, AVPR2 for TAL, SLC12A3 for DCT and AQP-2 for CCD.


β3-AR protein detected by polyclonal antibodies was present at the glomerular and tubular level in all renal samples with more intense staining in tubules from GD patients. β3-AR staining was also present in normal tubules from ADPKD samples but it was reduced in cystic tubules. Immunofluorescence studies performed using monoclonal antibodies showed β3-AR colocalization with tubular markers in TAL, DCT and CCD.


This is the first report on β3-AR localization in human kidney. Our data demonstrate that β3-AR is present in glomeruli and in nephron segments involved in water and solute reabsorption. The presence of this receptor in tissue from normal and diseased kidney suggests that further studies elucidating the physiology of β3-AR could lead to the identification of a new potential therapeutic targets in the treatment of renal diseases.